

## Qelbree - (150 mg ; Extended-Release Capsules)

<b>Generic Name</b>	Viloxazine Hydrochloride	<b>Innovator</b>	SUPERNUS PHARMS
<b>Dosage</b>	150 mg ; Extended-Release Capsules	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	More Than 5	<b>Known Para IV Filers</b>	More Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Qelbree - (100 mg; Extended-Release Capsules)

<b>Generic Name</b>	Viloxazine Hydrochloride	<b>Innovator</b>	SUPERNUS PHARMS
<b>Dosage</b>	100 mg; Extended-Release Capsules	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	More Than 5	<b>Known Para IV Filers</b>	More Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Qelbree - (200 mg; Extended-Release Capsules)

<b>Generic Name</b>	Viloxazine Hydrochloride	<b>Innovator</b>	SUPERNUS PHARMS
<b>Dosage</b>	200 mg; Extended-Release Capsules	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	More Than 5	<b>Known Para IV Filers</b>	More Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.